Bruno Moulin

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Genetics and Outcome of Atypical Hemolytic Uremic Syndrome

Véronique Frémeaux‐Bacchi, Fádi Fakhouri, Arnaud Garnier et al. · Clinical Journal of the American Society of Nephrology · 2013 · 713 citations

Life Sciences, Genetics, Nephrology +16

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies

Aude Servais, Laure‐Hélène Noël, Lubka T. Roumenina et al. · Kidney International · 2012 · 567 citations

Medicine, Immunology, Nephrology +17

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

Éric Thervet, Marie‐Anne Loriot, S. Barbier et al. · Clinical Pharmacology & Therapeutics · 2010 · 363 citations

Medicine, Pharmacokinetics, Pharmacology +17

Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome

Moglie Le Quintrec, Julien Zuber, Bruno Moulin et al. · American Journal of Transplantation · 2013 · 267 citations · Full text

Medicine, Immunology, Nephrology +17